1 The EIC Accelerator Project

EIC Accelerator Program Overview

The EIC Accelerator program is a pivotal funding initiative under the European Innovation Council (EIC) aimed at supporting small and medium-sized enterprises (SMEs), particularly those engaged in deep-tech innovations. Launched to enhance the competitiveness of European startups and scale-ups, the EIC Accelerator provides substantial financial assistance through a blended finance model, which combines grants and equity investments. The program is designed to foster groundbreaking technologies and innovative business models, ultimately contributing to economic growth and job creation within the European Union.

Funding Structure

The EIC Accelerator offers financial support of up to €2.5 million in the form of a grant, intended to cover various expenses related to the development and scaling of innovative projects. This grant can be utilized for research and development, prototyping, and other essential activities that enhance a company’s technological capabilities.

In addition to the grant, the EIC Accelerator provides equity funding, which has evolved over time. Until 2024, companies can access equity investments of up to €15 million, while the limit has been adjusted to €10 million from 2025 onwards. This equity investment is crucial for startups seeking to scale operations, enhance their market presence, and attract additional private sector funding. By facilitating access to capital, the EIC Accelerator plays a significant role in bridging the funding gap often experienced by innovative firms in the early stages of their development.

Purpose and Impact on the DeepTech Ecosystem

The EIC Accelerator serves as a critical support mechanism for the European DeepTech ecosystem. By focusing on high-risk, high-reward innovations, the program encourages entrepreneurial spirit and technological advancements that can lead to significant societal and economic benefits. The initiative targets sectors that require substantial investment and a longer time to market, which are often overlooked by traditional investors. As a result, the EIC Accelerator nurtures a diverse range of technologies, from healthcare solutions to sustainable energy initiatives, aligning with the European Union's strategic objectives.

Support for Scaling and Funding

One of the key roles of the EIC Accelerator is to assist companies in scaling their operations and securing additional funding from private sectors. By providing initial financial backing, the program enhances the credibility of startups, making them more attractive to private investors and venture capitalists. Furthermore, the EIC Accelerator offers tailored business coaching, mentoring, and access to a vast network of industry experts, which supports companies in refining their business models and go-to-market strategies. This comprehensive support enhances the likelihood of success for innovative projects and fosters a robust entrepreneurial ecosystem in Europe.

Case Study: METHINKS SOFTWARE S.L.

METHINKS SOFTWARE S.L., a winner of the EIC Accelerator, has developed a groundbreaking project known as Deepstroke-Acc. This initiative aims to revolutionize the diagnosis and treatment evaluation of strokes, providing accurate assessments in hospitals at any time. The project addresses a pressing need for timely and precise stroke interventions, which are critical for improving patient outcomes.

Project Overview

Deepstroke-Acc leverages advanced artificial intelligence (AI) algorithms to analyze medical imaging data and patient information, enabling healthcare professionals to make informed decisions regarding treatment options. The technology is designed to operate seamlessly across different hospital settings, ensuring that even remote or resource-limited facilities can access state-of-the-art diagnostic capabilities.

Technological Background

The underlying technology of Deepstroke-Acc integrates machine learning and data analytics to enhance stroke diagnosis. By utilizing extensive datasets and training algorithms on diverse medical cases, the system can identify patterns and predict outcomes with remarkable accuracy. This capability is crucial in emergency situations where every second counts, allowing clinicians to assess the most effective treatment options quickly.

The AI-driven platform operates by synthesizing data from various sources, including CT scans, MRI images, and patient histories. It provides real-time insights that empower healthcare providers to choose the best course of action, whether that involves immediate intervention or more conservative management strategies. The innovative approach not only improves diagnostic accuracy but also streamlines the decision-making process, ultimately leading to better patient care.

In conclusion, the EIC Accelerator program represents a significant step forward in supporting innovative startups like METHINKS SOFTWARE S.L. and their pioneering projects. By providing essential funding and resources, the program plays a crucial role in driving technological advancements and enhancing the European DeepTech ecosystem.

2 The Funding Rounds

Methinks Software S.L. (Methinks AI), a Spanish digital health company specializing in AI-driven early detection and management of acute stroke patients, has successfully raised a total of approximately $5.27 million through three funding rounds since its founding in 2016. The company’s financing history and investor details are as follows:

Financing Raised and Funding Rounds

• Total capital raised: About $5.27 million over 3 rounds.
• Funding rounds:
• December 7, 2020: Awarded funding from a Business Plan Competition (amount undisclosed).
• November 7, 2022: Received a grant from the European Innovation Council (EIC) Accelerator program under Horizon Europe (amount undisclosed but reported elsewhere as €2.5 million).
• November 14, 2023: Closed a Convertible Note round raising €2.5 million (~$2.72 million) with participation from the EIC Fund and other investors to prepare for an upcoming investment round.

Timing and Amounts

• The significant recent funding event was the convertible loan secured on November 14, 2023, amounting to €2.5 million.
• Prior to that were earlier grants/awards linked to business plan competitions and EIC Accelerator grants dating back to late 2020 and mid-2022 respectively.

Investor Information

• Key investors include:
• The European Innovation Council (EIC) Fund, which participated both through its grant program and equity investment via convertible notes.
• Other undisclosed private investors joined alongside EIC Fund in the latest convertible note round.

The involvement of the EIC Fund is strategic in supporting Methinks AI’s scaling efforts ahead of their planned Series A funding round expected in late H1 or H2 of 2024.

Company Valuations

Specific valuation figures for each funding stage have not been publicly disclosed; reported valuations remain unspecified or marked as “XXM” for confidentiality reasons during these early stages.

Exit Events

• As of April 2025, Methinks Software S.L./Methinks AI has not undergone any exit events such as IPOs or acquisitions.
• Instead, they are currently focused on product commercialization with regulatory milestones achieved including CE Mark certification obtained by January prior year and anticipated FDA clearance expected mid-next year facilitating entry into US markets.

Additional Context

Methinks AI develops software that uses artificial intelligence on non-contrast CT scans for rapid detection of large vessel occlusions causing strokes—critical insights that improve treatment timing significantly across hospitals with varying imaging capabilities.

This innovative technology attracted EU institutional support recognizing its clinical impact potential along with cost efficiencies for healthcare systems.

The recent injection via convertible notes is intended as preparatory capital enabling Methinks AI to scale operations ahead of their first major institutional equity round planned later this year.

---

Summary Table

Date	Round	Amount Raised	Investors	Notes
Dec.7,2020	Business Plan Comp.	Undisclosed	Unknown	Early-stage award
Nov.7,2022	Grant	~€2.5M	EIC Accelerator	Horizon Europe support
Nov.14,2023	Convertible Note	€2.5M ($~2.72M)	EIC Fund + Undisclosed Investors	Preparing Series A; strategic backing

---

No public information indicates any IPO or acquisition exits yet; current focus remains on regulatory approvals and commercial launch expansion primarily targeting stroke care markets globally including USA.

Sources

• Methinks AI Financials CB Insights
• Startups Real – Methinks closes €2.5m investment
• CB Insights – Methinks AI overview

3 The Press Releases

Methinks AI Advances Stroke Care Through AI-Driven Innovations and Strategic Partnerships Since securing EIC Accelerator funding in June 2022, Methinks Software S.L. (methinks.ai) has accelerated its mission to transform stroke care using artificial intelligence (AI). The Spain-based company has focused on expanding access to life-saving treatments through partnerships, clinical trials, and CE-marked technologies optimized for non-contrast CT imaging.

Key Developments

Technology Advancements

• Non-Contrast Imaging Focus: Unlike traditional methods requiring CT angiography or perfusion—available in fewer than half of global hospitals—Methinks’ algorithms analyze standard NCCT scans with high accuracy:
• LVO detection: 87.2% sensitivity, 87.7% specificity
• Hemorrhage detection: 97.3% sensitivity, 99.4% specificity
• Microsoft Teams Integration: Its coordination platform operates within Microsoft Teams workflows, enabling real-time collaboration between stroke teams while adhering to enterprise-grade security standards.

Leadership & Global Reach

CEO Pau Rodríguez emphasizes scalability as a core priority, supported by endorsements from leading neurologists such as Tudor Jovin (Cooper Neurological Institute) and Santiago Ortega-Gutiérrez (University of Iowa). Recent deployments at Hospital Vall d’Hebron (Spain) and Granollers General Hospital highlight improved workflow efficiency in real-world settings.

---

Sources

• Medtronic announces strategic partnership with Methinks AI
• DONE SYMPLE trial details
• Granollers General Hospital case study
• CE Mark announcement
• Technology specifications[Note: URL corrected from input data; original link may be typoed]

Additional sources derived from methints.ai press pages are referenced above but not directly linked due to URL formatting ambiguities.

4 The Technology Advancements

Methinks Software S.L. - Current Capabilities and Advancements

Methinks Software S.L., based in Spain, has been at the forefront of developing AI-driven medical imaging software, particularly for stroke diagnosis and management. Since receiving EIC Accelerator funding on June 15, 2022, the company has made significant advancements in its technology and market presence.

Current Capabilities

Methinks AI's primary offering is the Methinks Stroke Suite, which uses artificial intelligence algorithms to detect large vessel occlusions (LVO) and intracerebral hemorrhages (ICH) from non-contrast computed tomography (NCCT) images. This software is the first CE-marked medical device capable of identifying both hyperdense and non-hyperdense LVOs from NCCT and computed tomography angiography (CTA) images. The technology works in parallel with clinical workflows and leverages widely available CT scans, making it suitable for global use in hospitals.

Advancements and Improvements

Since the funding, Methinks has continued to enhance its technology. The company has emphasized the scalability and accessibility of its software through integration with Microsoft Teams, expanding its reach and impact on global stroke care. Additionally, Methinks AI has partnered with Medtronic to strengthen stroke treatment pathways across key regions, including Central and Eastern Europe, Africa, Türkiye, and the Middle East. This partnership highlights the company's commitment to improving stroke care by integrating AI-driven triage tools with existing medical device solutions.

Market Demonstration and Clinical Trials

Methinks AI has been involved in significant clinical trials and demonstrations. The company's technology has been validated in over 3,800 cases from leading stroke reference hospitals. Moreover, Methinks AI has been selected as the patient selection software for the DONE SYMPLE trial, a randomized controlled trial aimed at simplifying imaging protocols for late-window stroke patients. This trial will utilize Methinks' AI modules for LVO detection and ischemia volume measurement, further demonstrating the technology's potential in real-world settings.

New Patents, Scientific Studies, and Publications

There is no specific information available regarding new patents filed or scientific studies published by Methinks Software S.L. since receiving the EIC Accelerator funding. However, the company's continual involvement in clinical trials and partnerships suggests ongoing research and development efforts.

Sources

• Methinks AI Stroke Solutions
• Methinks AI - Microsoft 365 App Certification
• Methinks receives CE Marked Certification for AI-based stroke triage software
• Methinks Software SL
• Methinks gets CE mark for AI-based stroke triage software
• Medtronic Partners with Methinks AI to Enhance Stroke Care
• DONE SYMPLE trial to leverage Methinks AI's stroke assessment software

5 The Partnerships and Customers

Methinks Software S.L. Overview

Methinks Software S.L., headquartered in Spain, has been a standout in the digital health sector since receiving the EIC Accelerator funding in June 2022. The company specializes in developing AI-powered solutions for early detection and management of acute stroke patients. Their innovative approach has garnered significant attention and partnerships, positioning them for substantial growth in the healthcare technology market.

Partnerships and Customers

Recent Partnerships

• Medtronic Partnership: In April 2025, Methinks AI announced a strategic partnership with Medtronic, a global leader in healthcare technology. This collaboration aims to enhance stroke treatment pathways across Central and Eastern Europe, Africa, Turkey, and the Middle East by integrating Methinks AI's AI-driven radiological triage and notification systems with Medtronic's Neurovascular portfolio.
• Microsoft Teams Integration: Methinks AI has also strengthened its integration with Microsoft Teams, enabling seamless communication and coordination among healthcare professionals. This partnership enhances the accessibility and scalability of Methinks AI's technology worldwide.

New Partners and Customers

While specific new customers have not been detailed in recent announcements, the partnerships with notable entities like Medtronic and Microsoft are significant for expanding Methinks AI's reach. These alliances not only increase the visibility of Methinks AI's solutions but also contribute to its technology advancements by integrating with established healthcare systems.

Nature of New Relationships

The partnerships with Medtronic and Microsoft reflect Methinks AI's commitment to integrating AI-driven solutions into mainstream healthcare systems. By leveraging Medtronic's extensive network and Microsoft's technological infrastructure, Methinks AI aims to streamline stroke care coordination and enhance treatment outcomes across diverse geographic regions.

Positioning in the Market

These strategic relationships position Methinks AI as a leading innovator in stroke care technology. By collaborating with major healthcare technology companies, Methinks AI is poised to scale its operations and increase its market presence, particularly in regions with limited access to advanced imaging technologies.

Technology Advancements and Scaling

The partnerships facilitate technology advancements by allowing Methinks AI to refine its AI algorithms through access to more diverse and extensive datasets. Additionally, integrating with established healthcare systems accelerates the adoption of Methinks AI's solutions, enabling faster and more effective stroke care globally. The investments from the European Innovation Council (EIC) Fund further support Methinks AI's growth plans, including preparations for a significant Series A funding round in 2024.

Sources

• Methinks AI Stroke Solutions
• Product - Methinks AI
• Methinks AI - Microsoft 365 App Certification
• Methinks AI - Microsoft AppSource
• Methinks closes €2.5 million investment round
• Medtronic Partners with Methinks AI to Enhance Stroke Care
• DONE SYMPLE trial to leverage Methinks AI's stroke assessment software
• Medtronic inks stroke AI partnership with European developer Methinks

6 The Hiring and Company Growth

Methinks Software S.L. Overview

Methinks Software S.L., a Spanish company, is a prominent player in AI-driven radiological triage and notification systems, particularly for stroke assessment. Since receiving EIC Accelerator funding in June 2022, the company has experienced significant growth and development.

Team Growth and Hiring

• Current Headcount and Team Size: Specific figures for the current headcount or team size are not publicly available. However, Methinks AI has been expanding its team, with some team members joining as early as January 2023.
• Hiring Status: There is no explicit information on whether Methinks Software S.L. is currently hiring. However, the company's growth suggests ongoing recruitment efforts to support its expanding operations.
• Growth Since Funding: Since receiving the EIC Accelerator funding, Methinks AI has engaged in significant partnerships and project collaborations. For instance, the company partnered with Medtronic to enhance stroke care across various regions. Additionally, Methinks AI was selected as the patient selection software for the DONE SYMPLE trial, further indicating its growth and recognition in the medical AI sector.
• Key Positions: Specific key positions recently hired are not detailed, but the company's involvement in high-profile projects suggests the addition of skilled professionals in AI development, medical imaging analysis, and collaboration management.
• Impact on Scalability and Growth: New team members are crucial for Methinks AI as they contribute to developing advanced AI solutions for stroke assessment. These additions help the company scale by enhancing its product offerings, improving research capabilities, and supporting strategic partnerships. This growth enables Methinks AI to expand its influence in the healthcare sector, particularly in regions with limited access to advanced imaging technologies.
• Management and Founding Team Changes: There is no specific information available about major changes in management or the founding team of Methinks Software S.L. However, the company has a diverse board, including members like Dr. Tudor Jovin and others.

Future Outlook

Methinks AI is poised for continued growth, driven by its innovative AI solutions and strategic partnerships. The integration of its software with platforms like Microsoft Teams enhances scalability and accessibility, making it a key player in global stroke care. The company's participation in significant medical trials and collaborations underscores its commitment to advancing healthcare technology and improving patient outcomes.

Sources

• Methinks AI Team
• Methinks AI Research
• Methinks AI - Microsoft 365 App Certification
• Medtronic Partners with Methinks AI to Enhance Stroke Care
• DONE SYMPLE trial to leverage Methinks AI's stroke assessment software
• Brainomix Receives FDA Clearance for Stroke AI Imaging Software

7 The Media Features and Publications

Overview of Methinks Software S.L.

Methinks Software S.L., based in Barcelona, Spain, is a digital health company focused on developing AI-based medical imaging software, particularly for stroke diagnosis and treatment. The company gained significant recognition after receiving the EIC Accelerator funding in June 2022.

Media Features and Publications

Methinks has been featured in several publications, including Medtronic's announcement of a strategic partnership with Methinks AI to advance stroke care development. Additionally, Methinks received CE Mark certification for its AI-based stroke triage software, which has been covered by news outlets such as BioWorld. The company's Methinks Stroke Suite is recognized as a disruptive technology capable of early detection of large vessel occlusions from non-contrast computed tomographies (NCCT).

Content from Publications

Publications highlight Methinks' innovative approach to stroke care using AI. The company's software is noted for its ability to work with NCCT scans, which are widely available in hospitals, making it scalable globally. The partnership with Medtronic aims to streamline connectivity between stroke centers, enhancing treatment outcomes.

Podcasts and Interviews

There is no specific information available about podcasts or interviews featuring Methinks' team members. However, the company's purposeful mission and collaborative team environment are highlighted on their website.

Conference and Fair Visits

Methinks likely participates in healthcare technology conferences and events, but specific details about their participation in these events are not readily available. Given the nature of their technology, they might be involved in neurology or medical imaging conferences.

Involvement in Events

Methinks is working towards U.S. FDA approval following its CE Mark certification, indicating active involvement in the medical technology community and regulatory processes. The company's focus on improving stroke care through AI might involve collaborative efforts with hospitals and research institutions, such as Hospital Vall d'Hebron.

---

Sources

• Methinks AI Stroke Solutions
• Medtronic announces strategic partnership with Methinks AI
• Methinks receives CE Marked Certification for AI-based stroke triage software
• Methinks gets CE mark for AI-based stroke triage software
• Careers - Methinks AI
• Methinks sets sights on FDA approval after CE mark win for stroke software